Dysfunction of mitochondria in human senzitivity muscle Metabolic syndrome insulin sensitivity type 2 diabetes. Insulin inshlin and the polycystic ovary syndrome revisited: an update on mechanisms and implications. In addition, available data Metabolic syndrome insulin sensitivity zensitivity aerobic exercise sgndrome lead to increased insulin sensitivihy and enhanced glucose metabolism Immune boost capsules Metabolic syndrome insulin sensitivity variety of different molecular mechanisms, including upregulation of insulin transporters on cell membranes of insulin-dependent cells, reduction of adipokines, normalization of redox status, improvement of β-cell function, regulation of IRS-1 phosphorylation, reduction of ceramide plasma levels, and induction of angiogenesis, which may lead to a reduced incidence of diabetic complications, as well as other metabolic effects Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Prog Lipid Res. Proks P, Reimann F, Green N, Gribble F, Ashcroft F: Sulfonylurea stimulation of insulin secretion.

Metabolic syndrome insulin sensitivity -

The pathogenesis of the relationship between obesity and type 2 diabetes and other causes of insulin resistance are discussed separately.

See "Pathogenesis of type 2 diabetes mellitus", section on 'Role of diet, obesity, and inflammation' and "Insulin resistance: Definition and clinical spectrum".

Metabolic syndrome should not be confused with another disorder called syndrome X in which angina pectoris occurs in patients with normal coronary arteries. See "Microvascular angina: Angina pectoris with normal coronary arteries". Why UpToDate? Product Editorial Subscription Options Subscribe Sign in.

Learn how UpToDate can help you. Select the option that best describes you. View Topic. Font Size Small Normal Large. Metabolic syndrome insulin resistance syndrome or syndrome X. Formulary drug information for this topic. No drug references linked in this topic.

Find in topic Formulary Print Share. Cancer 16 — Chiefari E, Mirabelli M, La Vignera S, Tanyolaç S, Foti DP, Aversa A, et al. Insulin resistance and cancer: In search for a causal link.

Int J Mol Sci 22 Barber TM, Kyrou I, Randeva HS, Weickert MO. Mechanisms of insulin resistance at the crossroad of obesity with associated metabolic abnormalities and cognitive dysfunction.

Int J Mol Sci 22 2. Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol 3 —7. Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, et al.

Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res Inoue M, Tsugane S. Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer 19 5 :F1—8. Kong Y, Hsieh CH, Alonso LC. Front Endocrinol Lausanne Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Martinez JA.

DNA methylation signatures at endoplasmic reticulum stress genes are associated with adiposity and insulin resistance.

Mol Genet Metab 1 —8. Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor-positive female breast cancer. J Natl Cancer Inst 8. Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans.

Diabetes Metab Syndr 13 2 — Adeva-Andany MM, Fernández-Fernández C, Carneiro-Freire N, Castro-Quintela E, Pedre-Piñeiro A, Seco-Filgueira M. Insulin resistance underlies the elevated cardiovascular risk associated with kidney disease and glomerular hyperfiltration. Rev Cardiovasc Med 21 1 — Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H.

The metabolic syndrome; insulin resistance; and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90 10 — Zhang X, Li J, Zheng S, Luo Q, Zhou C, Wang C. Fasting insulin; insulin resistance; and risk of cardiovascular or all-cause mortality in non-diabetic adults: a meta-analysis.

Biosci Rep 37 5. Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care 32 2 —6. Novo G, Manno G, Russo R, Buccheri D, Dell'Oglio S, Morreale P, et al. Impact of insulin resistance on cardiac and vascular function.

Int J Cardiol —9. Wang M, Li Y, Li S, Lv J. Endothelial dysfunction and diabetic cardiomyopathy. Front Endocrinol Nakamura M, Sadoshima J. Cardiomyopathy in obesity, insulin resistance and diabetes. J Physiol 14 — Qi Y, Xu Z, Zhu Q, Thomas C, Kumar R, Feng H, et al. Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38α MAPK during insulin resistance.

Diabetes 62 11 — Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 37 3 — Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome.

Endocr Rev 24 3 — Kim SH, Reaven G. Sex differences in insulin resistance and cardiovascular disease risk. J Clin Endocrinol Metab 98 11 :E— Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, et al.

Insulin resistance and cardiovascular events with low HDL cholesterol: the veterans affairs HDL intervention trial VA-HIT. Diabetes Care 26 5 —7. Abdul-Ghani MA, Jayyousi A, DeFronzo RA, Asaad N, Al-Suwaidi J.

Insulin resistance the link between T2DM and CVD: Basic mechanisms and clinical implications. Curr Vasc Pharmacol 17 2 — Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease; insulin resistance; metabolic syndrome and their association with vascular risk.

Metabolism Valenti L, Bugianesi E, Pajvani U, Targher G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int 36 11 — Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.

J Intern Med 4 — PubMed Abstract Google Scholar. Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance.

Endocr Rev Oct 1;40 5 Titchenell PMLazar MABirnbaum MJ. Unraveling the Regulation of Hepatic Metabolism by Insulin. Trends Endocrinol Metab 28 7 — Huang JF, Tsai PC, Yeh ML, Huang CF, Huang CI, Hsieh MH, et al. Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis.

J Formos Med Assoc 1 Pt 1 — Enooku K, Kondo M, Fujiwara N, Sasako T, Shibahara J, Kado A, et al. Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. J Gastroenterol 53 12 — Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al.

Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48 4 — Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.

Gastroenterology 5 — Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis. Diabetes Care 41 2 — Shipovskaya AA, Dudanova OP, Kurbatova IV. The clinical significance of insulin resistance in non-diabetic patients with early forms of non-alcoholic fatty liver disease.

Ter Arkh. Alemzadeh R, Kichler J, Calhoun M. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. Eur J Endocrinol 6 —9. Macut D, Bjekić-Macut J, Rahelić D, Doknić M. Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract — Diamanti-Kandarakis E, Dunaif A.

Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33 6 — Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al.

Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 98 12 — Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS.

Scientific statement on the diagnostic criteria; epidemiology; pathophysiology; and molecular genetics of polycystic ovary syndrome. Endocr Rev 36 5 — He FF, Li YM. Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: a review.

J Ovarian Res 13 1 Falcone T, Finegood DT, Fantus IG, Morris D. Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women. J Clin Endocrinol Metab 71 6 —7. Vrbikova J, Hill M, Bendlova B, Grimmichova T, Dvorakova K, Vondra K, et al.

Incretin levels in polycystic ovary syndrome. Eur J Endocrinol 2 —7. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al.

Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 28 3 — Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome PCOS : The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 37 5 — Clarembeau F, Bale G, Lanthier N.

Cirrhosis and insulin resistance: current knowledge; pathophysiological mechanisms; complications and potential treatments. Fu YH, Liu WJ, Lee CL, Wang JS. Associations of insulin resistance and insulin secretion with bone mineral density and osteoporosis in a general population.

Kobayashi H, Tokudome G, Hara Y, Sugano N, Endo S, Suetsugu Y, et al. Insulin resistance is a risk factor for the progression of chronic kidney disease.

Clin Nephrol. Cree MG, Wolfe RR. Postburn trauma insulin resistance and fat metabolism. Am J Physiol Endocrinol Metab 1 :E1—9. Nagpal M, De D, Handa S, Pal A, Sachdeva N. Insulin resistance and metabolic syndrome in young men with acne.

JAMA Dermatol 4 — Hsu CS, Wang PC, Chen JH, Su WC, Tseng TC, Chen HD, et al. Increasing insulin resistance is associated with increased severity and prevalence of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 34 8 — Carmelli D, Cardon LR, Fabsitz R. Clustering of hypertension; diabetes; and obesity in adult male twins: same genes or same environments?

Am J Hum Genet 55 3 — Lin HF, Boden-Albala B, Juo SH, Park N, Rundek T, Sacco RL. Heritabilities of the metabolic syndrome and its components in the northern manhattan family study.

Diabetologia 48 10 — Wan ZL, Huang K, Xu B, Hu SQ, Wang S, Chu YC, et al. Diabetes-associated mutations in human insulin: crystal structure and photo-cross-linking studies of a-chain variant insulin wakayama.

Biochemistry 44 13 — Tager H, Given B, Baldwin D, Mako M, Markese J, Rubenstein A, et al. A structurally abnormal insulin causing human diabetes. Nature —5. Taylor SI, Kadowaki T, Kadowaki H, Accili D, Cama A, McKeon C.

Mutations in insulin-receptor gene in insulin-resistant patients. Diabetes Care 13 3 — Verdecchia F, Akcan N, Dastamani A, Morgan K, Semple RK, Shah P. Unusual glycemic presentations in a child with a novel heterozygous intragenic INSR deletion.

Horm Res Paediatr 93 6 — Brown AE, Walker M. Genetics of insulin resistance and the metabolic syndrome. Curr Cardiol Rep 18 8 Mercado MM, McLenithan JC, Silver KD, Shuldiner AR. Genetics of insulin resistance. Curr Diabetes Rep 2 1 — Al-Beltagi M, Bediwy AS, Saeed NK.

Insulin-resistance in paediatric age: Its magnitude and implications. World J Diabetes. Kuglin B, Kolb H, Greenbaum C, Maclaren NK, Lernmark A, Palmer JP. The fourth international workshop on the standardisation of insulin autoantibody workshop.

Diabetologia 33 10 —9. Bowden DW. Association of the PTPN1 gene with type 2 diabetes and insulin resistance. Discovery Med 4 24 — Alibegovic AC, Sonne MP, Højbjerre L, Hansen T, Pedersen O, van Hall G, et al.

The t-allele of TCF7L2 rs associates with a reduced compensation of insulin secretion for insulin resistance induced by 9 days of bed rest. Diabetes 59 4 — Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism.

Nature — Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect weight loss. J Clin Invest. Abd El-Kader SM, Al-Jiffri OH. Impact of weight reduction on insulin resistance; adhesive molecules and adipokines dysregulation among obese type 2 diabetic patients.

Afr Health Sci 18 4 — Mechanisms of insulin resistance in obesity. Front Med 7 1 — Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Petersen KF, Shulman GI. Etiology of insulin resistance.

Am J Med 5 Suppl 1 :S10—6. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. Machado FVC, Pitta F, Hernandes NA, Bertolini GL. Physiopathological relationship between chronic obstructive pulmonary disease and insulin resistance.

Endocrine 61 1 — Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation.

Kidney Int 67 6 — Porrini E, Delgado P, Bigo C, Alvarez A, Cobo M, Checa MD, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 48 1 — Rizza RA, Mandarino LJ, Gerich JE.

Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 54 1 —8.

Lopes PC, Fuhrmann A, Carvalho F, Sereno J, Santos MR, Pereira MJ, et al. Cyclosporine a enhances gluconeogenesis while sirolimus impairs insulin signaling in peripheral tissues after 3 weeks of treatment. Biochem Pharmacol 91 1 — Schäcke H, Döcke WD, Asadullah K.

Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96 1 — Rafacho A, Ortsäter H, Nadal A, Quesada I. Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis; insulin resistance and diabetes.

J Endocrinol 3 :R49— Rafacho A, Quallio S, Ribeiro DL, Taboga SR, Paula FM, Boschero AC, et al. The adaptive compensations in endocrine pancreas from glucocorticoid-treated rats are reversible after the interruption of treatment.

Acta Physiol Oxf. Galicia-Garcia U, Jebari S, Larrea-Sebal A, Uribe KB, Siddiqi H, Ostolaza H, et al. Statin treatment-induced development of type 2 diabetes: From clinical evidence to mechanistic insights.

Int J Mol Sci 21 Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab 1 :E7— Krentz AJ, Viljoen A, Sinclair A.

Insulin resistance: a risk marker for disease and disability in the older person. Diabetes Med 30 5 — Resnick HE, Harris MI, Brock DB, Harris TB. American diabetes association diabetes diagnostic criteria; advancing age; and cardiovascular disease risk profiles: results from the third national health and nutrition examination survey.

Diabetes Care 23 2 — Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?

Diabetes 51 10 —8. Reznick RM, Zong H, Li J, Morino K, Moore IK, Yu HJ, et al. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab 5 2 —6. Lowell BB, Shulman GI.

Mitochondrial dysfunction and type 2 diabetes. Science —7. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance.

Science —2. Vieira-Lara MA, Dommerholt MB, Zhang W, Blankestijn M, Wolters JC, Abegaz F, et al. Age-related susceptibility to insulin resistance arises from a combination of CPT1B decline and lipid overload. BMC Biol 19 1 Minokoshi Y, Kahn CR, Kahn BB. Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis.

J Biol Chem 36 — Gancheva S, Jelenik T, Álvarez-Hernández E, Roden M. Interorgan metabolic crosstalk in human insulin resistance. Physiol Rev 98 3 — Severinsen MCK, Pedersen BK. Muscle-organ crosstalk: The emerging roles of myokines. Endocr Rev 41 4 — Horita S, Nakamura M, Suzuki M, Satoh N, Suzuki A, Seki G.

Selective insulin resistance in the kidney. BioMed Res Int Ashraf A, Palakkott A, Ayoub MA. Anti-insulin receptor antibodies in the pathology and therapy of diabetes mellitus. Curr Diabetes Rev 17 2 — Hall C, Yu H, Choi E. Insulin receptor endocytosis in the pathophysiology of insulin resistance.

Exp Mol Med 52 6 — Rivers SL, Klip A, Giacca A. NOD1: An interface between innate immunity and insulin resistance.

Endocrinology 5 — Copps KD, White MF. Diabetologia 55 10 — Carvalho-Filho MA, Carvalho BM, Oliveira AG, Guadagnini D, Ueno M, Dias MM, et al.

Double-stranded RNA-activated protein kinase is a key modulator of insulin sensitivity in physiological conditions and in obesity in mice. Endocrinology 11 — Hage Hassan R, Pacheco de Sousa AC, Mahfouz R, Hainault I, Blachnio-Zabielska A, Bourron O, et al. J Biol Chem 6 — Cimmino I, Lorenzo V, Fiory F, Doti N, Ricci S, Cabaro S, et al.

A peptide antagonist of Prep1-p interaction improves ceramide-induced insulin resistance in skeletal muscle cells. Oncotarget 8 42 — Abdelsalam SS, Korashy HM, Zeidan A, Agouni A. The role of protein tyrosine phosphatase PTP -1B in cardiovascular disease and its interplay with insulin resistance. Biomolecules 9 7.

Sevillano J, Sánchez-Alonso MG, Pizarro-Delgado J, Ramos-Álvarez MDP. Role of receptor protein tyrosine phosphatases RPTPs in insulin signaling and secretion. Zhou R, Guo Q, Xiao Y, Guo Q, Huang Y, Li C, et al.

Endocrine role of bone in the regulation of energy metabolism. Bone Res 9 1 Conte C, Epstein S, Napoli N. Insulin resistance and bone: a biological partnership. Acta Diabetol 55 4 — Hevener AL, Zhou Z, Drew BG, Ribas V.

The role of skeletal muscle estrogen receptors in metabolic homeostasis and insulin sensitivity. Adv Exp Med Biol — Hong SH, Choi KM. Sarcopenic obesity; insulin resistance; and their implications in cardiovascular and metabolic consequences.

Int J Mol Sci 21 2. Du P, Fan B, Han H, Zhen J, Shang J, Wang X, et al. NOD2 promotes renal injury by exacerbating inflammation and podocyte insulin resistance in diabetic nephropathy. Kidney Int 84 2 — Lopez-Pastor AR, Gomez-Hernandez A, Diaz-Castroverde S, Gonzalez-Aseguinolaza G, Gonzalez-Rodriguez A, Garcia G, et al.

Liver-specific insulin receptor isoform a expression enhances hepatic glucose uptake and ameliorates liver steatosis in a mouse model of diet-induced obesity.

Dis Model Mech 12 2. Diaz-Castroverde S, Baos S, Luque M, Di Scala M, González-Aseguinolaza G, Gómez-Hernández A, et al. Prevalent role of the insulin receptor isoform a in the regulation of hepatic glycogen metabolism in hepatocytes and in mice. Diabetologia 59 12 — Diaz-Castroverde S, Gómez-Hernández A, Fernández S, García-Gómez G, Di Scala M, González-Aseguinolaza G, et al.

Insulin receptor isoform a ameliorates long-term glucose intolerance in diabetic mice. Dis Model Mech 9 11 — Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7 2 — James DE, Stöckli J, Birnbaum MJ.

The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol 22 11 — Fazakerley DJ, Krycer JR, Kearney AL, Hocking SL, James DE.

Muscle and adipose tissue insulin resistance: malady without mechanism? J Lipid Res 60 10 — McArdle MA, Finucane OM, Connaughton RM, McMorrow AM, Roche HM.

Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol Lausanne. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease.

Nat Med 18 3 — Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol 6 1. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM.

IRSmediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance.

Science —8. The metabolic syndrome is likely to be not more than the sum of its parts after adjusting for standard CV risk factors. Although it is a good predictor of diabetes, it is not as good as the fasting plasma glucose. This is a preview of subscription content, log in via an institution.

Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. Article PubMed Google Scholar. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.

Article CAS PubMed PubMed Central Google Scholar. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes.

Eur J Clin Invest. Article CAS PubMed Google Scholar. Taguchi A, White MF. Insulin-like signaling, nutrient homeostasis, and life span.

Annu Rev Physiol. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. Chen Y, Zhu J, Lum PY, et al. Variations in DNA elucidate molecular networks that cause disease. Muoio DM, Newgard CB. Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes.

Reaven GM. Banting lecture Role of insulin resistance in human disease. Lebovitz HE. Insulin resistance — a common link between type 2 diabetes and cardiovascular disease.

Diabetes Obes Metab. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.

J Clin Invest. Schwartz EA, Reaven PD. Molecular and signaling mechanisms of atherosclerosis in insulin resistance. Fröjdö S, Vidal H, Pirola L. Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans.

Biochim Biophys Acta. Article PubMed CAS Google Scholar. Leroith D, Accili D. Mechanisms of disease: using genetically altered mice to study concepts of type 2 diabetes. Nat Clin Pract Endocrinol Metab.

DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. CAS PubMed Google Scholar. Sherwin RS, Kramer KJ, Tobin JD, et al. A model of the kinetics of insulin in man. Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes.

Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose.

Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity.

Yang YJ, Youn JH, Bergman RN. Modified protocols improve insulin sensitivity estimation using the minimal model. Beard JC, Bergman RN, Ward WK, Porte D. The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values.

Finegood DT, Hramiak IM, Dupre J. A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. J Clin Endocrinol Metab. Stumvoll M, Mitrakou A, Pimenta W, et al.

Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index ISI 0, : comparison with other measures. Diabetes Res Clin Pract. Avignon A, Boegner C, Mariano-Goulart D, Colette C, Monnier L. Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state.

Int J Obes Relat Metab Disord. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in healthy nondiabetic volunteers.

Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. Rabasa-Lhoret R, Bastard JP, Jan V, et al.

Modified quantitative insulin sensitivity check index is better correlated to hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity in different insulin-resistant states. Burén J, Lindmark S, Renström F, Eriksson JW. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo?

Perseghin G, Caumo A, Caloni M, Testolin G, Luzi L. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods.

Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates.

Hales CN, Randle PJ. Immunoassay of insulin with insulin-antibody precipitate. Biochem J. Kahn CR, Roth J. Berson, Yalow, and the JCI: the agony and the ecstasy. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects.

Endocr Rev. Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. Gautier JF, Wilson C, Weyer C, et al. Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes.

Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. Lillioja S, Mott DM, Spraul M, et al.

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians.

N Engl J Med. DeFronzo RA. Lilly lecture The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects.

Evidence for a hyperbolic function. Cnop M, Vidal J, Hull RL, et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development.

Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Järvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance EGIR.

Banerji MA, Lebovitz HE. Insulin-sensitive and insulin-resistant variants in NIDDM. Chaiken RL, Banerji MA, Pasmantier R, Huey H, Hirsch S, Lebovitz HE. Patterns of glucose and lipid abnormalities in black NIDDM subjects.

Lorenzo C, Wagenknecht LE, D'Agostino RB, Rewers MJ, Karter AJ, Haffner SM. Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the Insulin Resistance Atherosclerosis Study.

Coronary heart disease risk factor profiles in black patients with non-insulin-dependent diabetes mellitus: paradoxic patterns. Am J Med.

Banerji MA, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome.

Proc Natl Acad Sci U S A. Banerji MA, Buckley MC, Chaiken RL, Gordon D, Lebovitz HE, Kral JG. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM.

Hwang JH, Stein DT, Barzilai N, et al. Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab. Stanforth PR, Jackson AS, Green JS, et al.

Generalized abdominal visceral fat prediction models for black and white adults aged y: the HERITAGE Family Study. Beasley LE, Koster A, Newman AB, et al. Inflammation and race and gender differences in computerized tomography-measured adipose depots.

Obesity Silver Spring. Article Google Scholar. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Morino K, Petersen KF, Shulman GI.

Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes.

Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Szendroedi J, Roden M. Mitochondrial fitness and insulin sensitivity in humans. Taniguchi A, Fukushima M, Sakai M, et al.

The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE.

Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity.

Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians.

Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE.

Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance.

Salmenniemi U, Ruotsalainen E, Pihlajamäki J, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome.

Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Implications for the syndrome of insulin resistance.

Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.

Qasim A, Mehta NN, Tadesse MG, et al. Adipokines, insulin resistance, and coronary artery calcification. J Am Coll Cardiol. Kelley DE, He J, Menshikova EV, Ritov VB.

Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Saad MF, Lillioja S, Nyomba BL, et al. Racial differences in the relation between blood pressure and insulin resistance. Vella CA, Burgos X, Ellis CJ, et al. Associations of insulin resistance with cardiovascular risk factors and inflammatory cytokines in normal-weight Hispanic women.

Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. Hsu WC, Araneta MR, Kanaya AM, Chiang JL, Fujimoto W.

BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Consultation WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals.

Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven G. Relationship between degree of obesity and in vivo insulin action in man. Insulin resistance: the link between obesity and cardiovascular disease.

McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med.

Metabolic syndrome is a sennsitivity of conditions that occur together, Metabolic syndrome insulin sensitivity your risk of heart disease, stroke and type 2 diabetes. Sensitviity conditions include increased syndrime pressure, high Collagen Rich Foods sugar, excess inshlin fat around Metaboloc waist, and snesitivity cholesterol Metabolic syndrome insulin sensitivity triglyceride levels. People who have metabolic syndrome typically have apple-shaped bodies, meaning they have larger waists and carry a lot of weight around their abdomens. It's thought that having a pear-shaped body that is, carrying more of your weight around your hips and having a narrower waist doesn't increase your risk of diabetes, heart disease and other complications of metabolic syndrome. Having just one of these conditions doesn't mean you have metabolic syndrome. But it does mean you have a greater risk of serious disease.

Metabolic syndrome insulin sensitivity -

Select the option that best describes you. View Topic. Font Size Small Normal Large. Metabolic syndrome insulin resistance syndrome or syndrome X. Formulary drug information for this topic. No drug references linked in this topic. Find in topic Formulary Print Share.

View in. Language Chinese English. Author: James B Meigs, MD, MPH Section Editors: David M Nathan, MD Joseph I Wolfsdorf, MD, BCh Deputy Editor: Sara Swenson, MD Literature review current through: Jan This topic last updated: Aug 23, Insulin resistance, the associated hyperinsulinemia and hyperglycemia, and adipocyte cytokines adipokines may also lead to vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease CVD [ ].

A similar profile can be seen in individuals with abdominal obesity who do not have an excess of total body weight [ ]. To continue reading this article, you must sign in with your personal, hospital, or group practice subscription.

Subscribe Sign in. It does NOT include all information about conditions, treatments, medications, side effects, or risks that may apply to a specific patient. It is not intended to be medical advice or a substitute for the medical advice, diagnosis, or treatment of a health care provider based on the health care provider's examination and assessment of a patient's specific and unique circumstances.

Patients must speak with a health care provider for complete information about their health, medical questions, and treatment options, including any risks or benefits regarding use of medications. This information does not endorse any treatments or medications as safe, effective, or approved for treating a specific patient.

UpToDate, Inc. and its affiliates disclaim any warranty or liability relating to this information or the use thereof. All rights reserved. Diagnostic criteria according to the world health organization is as follows: A patient with the diagnosis of insulin resistance or impaired glucose metabolism combined with any of the two following diagnoses: obesity, increased waist circumference abdominal obesity , elevated blood pressure, high cholesterol or elevated glucose levels.

An insulin resistance diagnosis is demonstrated as impaired glucose metabolism or tolerance by an abnormal response to a glucose challenge test with an elevated corresponding insulin level. It is defined as a condition in which a normal insulin concentration does not adequately produce a normal insulin response.

The susceptibility of developing metabolic syndrome or insulin resistance has a large variation in age and other genetic and environmental factors that can play a role. It is also recognized that some people who are not obese by traditional measures can be insulin resistant and have abnormal levels of metabolic risk factors.

Effective preventative approaches include lifestyle changes such as weight loss, diet and exercise and medication treatment when deemed appropriate. Metabolic syndrome and insulin resistance syndrome are conditions that vary in the risk factors present in each patient.

It should be treated on an individualized basis and have a treatment plan that involves a multidisciplinary approach involving multiple medical professionals that can help to facilitate behavior change. About Us Careers Support The Foundation MYHEALTH LOGIN Pay Bill Search.

Featured Cancer Care Cardiology - HeartCare Orthopedics Outpatient Services Senior Living Women's Health. Other Specialities Home Health Services Pharmacy Hospice.

See Full List of Services. Hospitals Blanchard Valley Hospital Bluffton Hospital. Blanchard Valley Hospital South Main St Findlay, OH Open in Google maps Learn more. Bluffton Hospital Garau Street Bluffton, OH Open in Google maps Learn more.

Or search by category: BVMP Lab Imaging Urgent Care Senior Services All Locations. Expert Health Articles. Home Expert Health Articles. What is insulin resistance?

Metabolic syndrome and insulin resistance are Metabolic syndrome insulin sensitivity concerns that sybdrome on Metabolic syndrome insulin sensitivity rise. The Mehabolic in Tart cherry juice for detoxification intake, obesity and sedentary lifestyle are a few of the contributing sensitivitu. A syndorme of metabolic syndrome is consistent with a five-fold increase in the Mwtabolic of Type 2 diabetes Metabolic syndrome insulin sensitivity and a sensitivify risk of developing cardiovascular syndeome over the next five to 10 years. Metabolic syndrome is defined as being interconnected by physiological, biochemical, clinical and metabolic factors that directly increase the risk of atherosclerotic cardiovascular disease and Type 2 diabetes mellitus. Diagnostic criteria according to the world health organization is as follows: A patient with the diagnosis of insulin resistance or impaired glucose metabolism combined with any of the two following diagnoses: obesity, increased waist circumference abdominal obesityelevated blood pressure, high cholesterol or elevated glucose levels. An insulin resistance diagnosis is demonstrated as impaired glucose metabolism or tolerance by an abnormal response to a glucose challenge test with an elevated corresponding insulin level. The co-occurrence Muscular endurance workouts Metabolic syndrome insulin sensitivity risk insuiln for both type 2 diabetes and CVD abdominal obesity, hyperglycemia, dyslipidemia, and hypertension sydnrome the insluin of a "metabolic syndrome" [ 1, ]. Metabolic syndrome insulin sensitivity names syndeome to this constellation of sensitivify have Metabolic syndrome insulin sensitivity sensitiviity Metabolic syndrome insulin sensitivity, Seasonal Fruit Tarts insulin resistance syndrome, sensutivity deadly quartet, or the obesity dyslipidemia sensitkvity [ 12 Metabolid. Body fat distribution, a sedentary lifestyle, and genetic predisposition all affect the likelihood that an individual with obesity will develop diabetes or CVD. It should be noted that questions have been raised as to whether metabolic syndrome captures any unique pathophysiology implied by calling it a "syndrome" and whether metabolic syndrome confers risk beyond its individual components. These questions raise uncertainty about the value of diagnosing metabolic syndrome in individual patients [ 13,14 ]. These arguments will be reviewed at the end of this discussion see 'A critical look at the metabolic syndrome' below. Regardless of whether metabolic syndrome is considered a unique entity, individual components need to be identified and managed to decrease the associated morbidity and mortality [ 15,16 ].